
OnKure Therapeutics, Inc.: shareholders and insiders
Price
$2.70
November 20, 2026Market cap $111M
What Ploutos Investor adds for OnKure Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 2 fiscal years, from 2024
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors, from their own Form 4 filings.
Reading the newest filings from the SEC. This part fills in on its own in a few seconds.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- AI Biotechnology LLCwith 3 more personsClass A Common Stock, par value $0.0001 per shareShare of class20.0%
- RA Capital Management, L.P.with 3 more personsClass A Common Stock, $0.0001 par value per shareShare of class9.90%
- Acorn Bioventureswith 4 more personsShare of class9.50%
- Biotechnology Value Fund L Pwith 9 more personsClass A Common Stock, par value $0.0001 per shareShare of class8.00%
- Coastlands Capital LPwith 4 more personsClass A Common Stock, par value $0.0001 per shareShare of class6.67%
- StepStone Group LPwith 2 more personsClass A Common Stock, par value $0.0001 per shareShare of class6.60%
- Shay Capital LLCwith 1 more personClass A Common Stock, par value $0.0001 per shareShare of class6.30%
- Trails Edge Capital Partners, LPwith 2 more personsClass A Common Stock, $0.0001 par value per shareShare of class6.00%
- ADAR1 Capital Management, LLCwith 2 more personsClass A Common Stock, par value $0.0001 per shareShare of class5.50%
- Cantor Fitzgerald Securitieswith 3 more personsClass A Common Stock, par value $0.0001 per shareShare of class5.20%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| AI Biotechnology LLCwith 3 more personsClass A Common Stock, par value $0.0001 per share | 20.0% | 9.09M | Apr 7, 2026 | 13D | |
| RA Capital Management, L.P.with 3 more personsClass A Common Stock, $0.0001 par value per share | 9.90% | 4.04M | Apr 7, 2026 | 13G | |
| Acorn Bioventureswith 4 more persons | 9.50% | 3.92M | Apr 1, 20263 filings since May 22, 2025 | 13G | |
| Biotechnology Value Fund L Pwith 9 more personsClass A Common Stock, par value $0.0001 per share | 8.00% | 3.24M | Aug 14, 20262 filings since May 27, 2026 | 13G/A | |
| Coastlands Capital LPwith 4 more personsClass A Common Stock, par value $0.0001 per share | 6.67% | 2.70M | Oct 7, 2026 | 13G | |
| StepStone Group LPwith 2 more personsClass A Common Stock, par value $0.0001 per share | 6.60% | 2.66M | Apr 7, 2026 | 13G | |
| Shay Capital LLCwith 1 more personClass A Common Stock, par value $0.0001 per share | 6.30% | 810.2K | May 29, 2025 | 13G | |
| Trails Edge Capital Partners, LPwith 2 more personsClass A Common Stock, $0.0001 par value per share | 6.00% | 2.41M | Apr 7, 2026 | 13G | |
| ADAR1 Capital Management, LLCwith 2 more personsClass A Common Stock, par value $0.0001 per share | 5.50% | 2.24M | Aug 14, 20263 filings since Feb 17, 2026 | 13G/A | |
| Cantor Fitzgerald Securitieswith 3 more personsClass A Common Stock, par value $0.0001 per share | 5.20% | 669.5K | Aug 14, 2025 | 13G |
What the holders on a 13D state as their purpose
From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.
AI Biotechnology LLC20.0%From the filing of Apr 7, 2026
The information set forth in Item 3 and Item 6 hereof is hereby incorporated herein by reference. The Reporting Persons who hold securities of the Issuer directly acquired those securities as an investment in the regular course of their businesses. The Reporting Persons may engage in discussions with management, the Issuer's board of directors, other stockholders of the Issuer and other relevant parties concerning the business, operations, board composition, management, strategy and future plans of the Issuer. Dr. Liam Ratcliffe, who is currently employed by Access Industries, Inc., an affiliate of AIB, as its Head of Biotechnology, serves on the board of directors of the Issuer (in…
From the filing of Apr 7, 2026
Fell to 5% or less (11)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
- Trails Edge Capital Partners, LP3.60%Aug 14, 202613G/A
- Prosight Management, LP2.40%Aug 10, 202613G/A
- Highbridge Capital Management, LLC4.20%Feb 17, 202613G/A
- Citadel Advisors LLC1.70%Feb 17, 202613G/A
- The Vanguard Group4.87%Jan 30, 202613G/A
- Perceptive Advisors LLC0.00%Aug 14, 202513G/A
- Samsara BioCapital, L.P.0.00%Aug 14, 202513G/A
- Cormorant Asset Management, LP0.00%May 19, 202513G/A
- Deep Track Capital, LP4.14%Feb 14, 202513G/A
- Lundbeckfond Invest A/S1.60%Feb 6, 202513G/A
- RiverVest Venture Fund III, L.P.13D1.55%Jan 21, 202513D/A
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Citadel Advisors (Griffin)In the quarter-53%
- Renaissance TechnologiesIn the quarter-1.6%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Citadel Advisors (Griffin) | 556.5K | -53% | $1.5M | 0.00% |
| Renaissance Technologies | 353.2K | -1.6% | $1.0M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 3.38% of its shares outstanding were held short, +13.2% since the report before.
- Shares held short
- 1.39M
- 3.38%
- Since the report before1.22M on Sep 30, 2026
- +13.2%
- 2.6
- 543.5K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 30%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 15, 2024: Shares held short 693.8K
- Oct 31, 2024: Shares held short 924.6K
- Nov 15, 2024: Shares held short 1.02M
- Nov 29, 2024: Shares held short 1.12M
- Dec 13, 2024: Shares held short 1.24M
- Dec 31, 2024: Shares held short 1.24M
- Jan 15, 2025: Shares held short 1.41M
- Jan 31, 2025: Shares held short 1.40M
- Feb 14, 2025: Shares held short 1.10M
- Feb 28, 2025: Shares held short 1.10M
- Mar 14, 2025: Shares held short 1.07M
- Mar 31, 2025: Shares held short 1.06M
- Apr 15, 2025: Shares held short 1.15M
- Apr 30, 2025: Shares held short 574.0K
- May 15, 2025: Shares held short 560.2K
- May 30, 2025: Shares held short 530.3K
- Jun 13, 2025: Shares held short 512.9K
- Jun 30, 2025: Shares held short 351.2K
- Jul 15, 2025: Shares held short 244.4K
- Jul 31, 2025: Shares held short 225.9K
- Aug 15, 2025: Shares held short 228.9K
- Aug 29, 2025: Shares held short 197.9K
- Sep 15, 2025: Shares held short 193.2K
- Sep 30, 2025: Shares held short 174.6K
- Oct 15, 2025: Shares held short 65.1K
- Oct 31, 2025: Shares held short 48.4K
- Nov 14, 2025: Shares held short 37.7K
- Nov 28, 2025: Shares held short 41.4K
- Dec 15, 2025: Shares held short 52.0K
- Dec 31, 2025: Shares held short 24.4K
- Jan 15, 2026: Shares held short 9,877
- Jan 30, 2026: Shares held short 14.2K
- Feb 13, 2026: Shares held short 33.4K
- Feb 27, 2026: Shares held short 53.8K
- Mar 13, 2026: Shares held short 7,962
- Mar 31, 2026: Shares held short 163.9K
- Apr 15, 2026: Shares held short 69.5K
- Apr 30, 2026: Shares held short 103.4K
- May 15, 2026: Shares held short 199.4K
- May 29, 2026: Shares held short 234.9K
- Jun 15, 2026: Shares held short 282.4K
- Jun 30, 2026: Shares held short 878.7K
- Jul 15, 2026: Shares held short 1.18M
- Jul 31, 2026: Shares held short 1.19M
- Aug 14, 2026: Shares held short 1.07M
- Aug 31, 2026: Shares held short 1.32M
- Sep 15, 2026: Shares held short 1.38M
- Sep 30, 2026: Shares held short 1.22M
- Oct 15, 2026: Shares held short 1.39M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading23.2% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 23.2% of the shares in the reported trades were short sales, against 61.9% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 23.2%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 61.9%
- Change
- -38.7 pts
- Short sales a dayon average, of 242.3K shares
- 56.2K
- More than atof 3,666 US-listed companies, same days
- 1%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 85.2%
- Oct 15, 2026: Short sales 75%
- Oct 16, 2026: Short sales 47.4%
- Oct 19, 2026: Short sales 65.2%
- Oct 20, 2026: Short sales 51.2%
- Oct 21, 2026: Short sales 64.4%
- Oct 22, 2026: Short sales 52.5%
- Oct 23, 2026: Short sales 56.2%
- Oct 26, 2026: Short sales 59.9%
- Oct 27, 2026: Short sales 78.9%
- Oct 28, 2026: Short sales 53.8%
- Oct 29, 2026: Short sales 31.2%
- Oct 30, 2026: Short sales 90.1%
- Nov 2, 2026: Short sales 74.7%
- Nov 3, 2026: Short sales 90.2%
- Nov 4, 2026: Short sales 3.9%
- Nov 5, 2026: Short sales 14.2%
- Nov 6, 2026: Short sales 27.8%
- Nov 9, 2026: Short sales 22.6%
- Nov 10, 2026: Short sales 62.1%
- Nov 11, 2026: Short sales 49.5%
- Nov 12, 2026: Short sales 73.3%
- Nov 13, 2026: Short sales 14.4%
- Nov 16, 2026: Short sales 11.6%
- Nov 17, 2026: Short sales 61.2%
- Nov 18, 2026: Short sales 80%
- Nov 19, 2026: Short sales 78.3%
- Nov 20, 2026: Short sales 65.5%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IWCiShares Micro-Cap ETFWeight in the fund0.02%
- IWNiShares Russell 2000 Value ETFWeight in the fund0.01%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.00%
- IWMiShares Russell 2000 ETFWeight in the fund0.00%
- VXFVanguard Extended Market Index FundWeight in the fund0.00%
- DFASDimensional U.S. Small Cap ETFWeight in the fund0.00%
- VTIVanguard Total Stock Market Index FundWeight in the fund0.00%
7 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 42
- Q4 2025: Managers 43
- Q1 2026: Managers 52
- Q2 2026: Managers 75
Institutional investors by quarter
The fund managers holding OKUR, quarter by quarter, from Q3 2024 to Q2 2025, 4 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 8 quarters.
Q2 2026: 75 managers held 34.97M shares, worth $159M. During the quarter 31 opened a position, 8 closed one, 20 added and 9 trimmed.
The largest holders, Q2 2026
- Ra Capital ManagementIn the quarter
- BvfIn the quarter+64%
- Acorn Capital AdvisorsIn the quarter
- StepStone GroupIn the quarter
- ADAR1 Capital ManagementIn the quarter-8.1%
- Vivo CapitalIn the quarter
- Vestal Point CapitalIn the quarter-0.8%
- BlackRockIn the quarter×30.2
- Trails Edge Capital PartnersIn the quarter
- Vanguard Capital ManagementIn the quarter+147%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Ra Capital Management | 4.00M | $18M | |
| Bvf | 3.24M | +64% | $15M |
| Acorn Capital Advisors | 2.84M | $13M | |
| StepStone Group | 2.66M | $12M | |
| ADAR1 Capital Management | 2.24M | -8.1% | $10M |
| Vivo Capital | 1.93M | $8.8M | |
| Vestal Point Capital | 1.83M | -0.8% | $8.3M |
| BlackRock | 1.50M | ×30.2 | $6.8M |
| Trails Edge Capital Partners | 1.44M | $6.6M | |
| Vanguard Capital Management | 1.44M | +147% | $6.6M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do OnKure Therapeutics's filings show?
Who buys and sells is one part of OnKure Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Which well-known managers hold OKUR?
2 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $1.5M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.